

1ST INTERNATIONAL CONSENSUS CONFERENCE

Management of the
Kidney Transplant
Patient with Cancer
Rome, 30 – 31 January 2020



Scientific Coordinator: Jacopo Romagnoli

AULA BRASCA – UNIVERSITÀ CATTOLICA DEL SACRO CUORE
FONDAZIONE POLICLINICO UNIVERSITARIO A. GEMELLI IRCCS

PROGRAMME



Endorsement



Committees

Organising Committee

Jacopo Romagnoli
Giovanni Scambia
Giampaolo Tortora
Vincenzo Valentini

Scientific Committee

Jacopo Romagnoli
Scientific Coordinator
Anna Acampora
Methodological Coordinator
Stefania Boccia
Giuseppe Grandaliano
Stefan Hohaus
Roberto Iacovelli
Roberto Iezzi
Umberto Maggiore
Ketty Peris
Ernesto Rossi
Giuseppe Scaletta
Giovanni Schinzari
Luca Tagliaferri

Work Group Members

Anna Acampora
Valentina Bianchi
Andrea D'Aviero
Ilaria Esposito
Stefan Hohaus
Valentina Lancellotta
Elena Maiolo
Filippo Paoletti
Alessandro Posa
Ernesto Rossi
Giuseppe Scaletta
Giovanni Schinzari
Gionata Spagnoletti
Luca Tagliaferri

Discussants and Chairs

Luigi Biancone
Emilio Bria
Vincenzo Cantaluppi
Franco Citterio
Valeriana Colombo
Laura Cosmai
Valerio Di Paola
Alessandro Di Stefani
Paola Donato
Lucrezia Furian
Maria Antonietta Gambacorta
Giuseppe Grandaliano
Rosario Francesco Grasso
Barbara Jereczek
György Kovács
Mario Luppi
Umberto Maggiore
Nizam Mamode
Alessandra Palmisano
Ketty Peris
Camillo Porta
Søren Schwartz Sorensen
Giampaolo Tortora
Vincenzo Valentini
Andrea Veltri
Fabio Vistoli
Bruno Watschinger

Thursday, 30 January 2020

14:15 – 14:45

WELCOME

Institutional Greetings

14:45 – 15:00

PRESENTATION OF THE CONFERENCE METHODOLOGY

Jacopo Romagnoli (*Rome*)

15:00 – 18:00

SESSION I

INTEGRATED THERAPY

Moderators: Vincenzo Valentini (*Rome*), Valerio Di Paola (*Rome*)

15:00 – 15:40

Does withdrawing antimetabolites and/or CNi inhibitors and/or mTOR-inhibitors as opposed to continuing maintenance immunosuppression improve patient survival in kidney transplant recipients with cancer undergoing radiotherapy?

Presenter: Luca Tagliaferri (*Rome*)

- 1st discussant: Valeriana Colombo (*Milan*)
- 2nd discussant: Barbara Jereczek (*Milan*)
- Discussion and voting

15:40 – 16:20

Should a kidney transplant patient with cancer avoid standard radiotherapy technique (EBRT, BT, SBRT, protons), dose and volume in order to preserve the transplanted kidney?

Presenter: Valentina Lancellotta (*Rome*)

- 1st discussant: Vincenzo Cantaluppi (*Novara*)
- 2nd discussant: Maria Antonietta Gambacorta (*Rome*)
- Discussion and voting

16:20 – 16:40

Coffee break

Thursday, 30 January 2020

16:40 – 17:20

In case of cancer of the transplanted kidney, is focal treatment (thermoablation, radiofrequency, brachytherapy, electrochemotherapy, cryoablation, stereobody radiotherapy, protons) indicated as the standard treatment as opposed to graft nephrectomy?

Presenter: Alessandro Posa (*Rome*)

- 1st discussant: Lucrezia Furian (*Padua*)
- 2nd discussant: Rosario Francesco Grasso (*Rome*)
- Discussion and voting

17:20 – 18:00

In case of focal treatment, is percutaneous approach (thermoablation, radiofrequency, brachytherapy, electrochemotherapy, cryoablation) indicated as the standard treatment as opposed to external beam radiotherapy (stereobody radiotherapy, protons)?

Presenter: Roberto Iezzi (*Rome*)

- 1st discussant: György Kovács (*Lübeck, Germany*)
- 2nd discussant: Andrea Veltri (*Turin*)
- Discussion and voting

18:00 – 18:10

CONCLUSIONS

Jacopo Romagnoli (*Rome*)

Friday, 31 January 2020

08:45 – 09:00	PRESENTATION OF THE CONFERENCE METHODOLOGY Jacopo Romagnoli (<i>Rome</i>)
09:00 – 11:00	SESSION IIA IMMUNOSUPPRESSIVE THERAPY Moderators: Franco Citterio (<i>Rome</i>), Umberto Maggiore (<i>Parma</i>)
09:00 – 09:40	Should immunosuppression be stopped or modified before oncological surgery in the kidney transplant recipient? Presenter: Giuseppe Scaletta (<i>Rome</i>) • 1st discussant: Nizam Mamode (<i>London, UK</i>) • 2nd discussant: Fabio Vistoli (<i>Pisa</i>) • Discussion and voting
09:40 – 10:20	Does maintaining as opposed to withdrawing or reducing calcineurin inhibitors in kidney transplant recipients with non-metastatic, non-skin cancer undergoing chemotherapy worsen patient or graft survival? Presenter: Valentina Bianchi (<i>Rome</i>) • 1st discussant: Bruno Watschinger (<i>Vienna, Austria</i>) • 2nd discussant: Laura Cosmai (<i>Milan</i>) • Discussion and voting
10:20 – 11:00	Does the switch from calcineurin inhibitors to mTOR-inhibitors improve patient or graft survival of kidney transplant recipients with metastatic non-skin cancer undergoing chemotherapy? Presenter: Gionata Spagnoletti (<i>Rome</i>) • 1st discussant: Søren Schwartz Sørensen (<i>Copenhagen, Denmark</i>) • 2nd discussant: Laura Cosmai (<i>Milan</i>) • Discussion and voting
11:00 – 11:20	Coffee Break

Friday, 31 January 2020

11:20 – 12:40

SESSION IIB

IMMUNOSUPPRESSIVE THERAPY AND IMMUNOTHERAPY

Moderators: Giuseppe Grandaliano (*Rome*), Ketty Peris (*Rome*)

11:20 – 12:00

Does maintaining as opposed to withdrawing calcineurin inhibitors in kidney transplant recipients with PTLD, undergoing first-line chemotherapy worsen patient or graft survival?

Presenter: Stefan Hohaus (*Rome*)

- 1st discussant: Paola Donato (*Verona*)
- 2nd discussant: Mario Luppi (*Modena*)
- Discussion and voting

12:00 – 12:40

Does the use of checkpoint inhibitors in kidney transplant recipients with metastatic skin and non-skin cancer have a negative impact on patient or graft survival?

Presenters: Ernesto Rossi / Ilaria Esposito (*Rome*)

- 1st discussant: Alessandra Palmisano (*Parma*)
- 2nd discussant: Alessandro Di Stefani (*Rome*)
- 3rd discussant: Emilio Bria (*Rome*)
- Discussion and voting

12:40 – 13:00

Lectio Magistralis

HOW TO DEAL WITH A SURGICAL CRISIS

Nizam Mamode (*London, UK*)

13:00 – 14:00

Lunch

Friday, 31 January 2020

14:00 – 17:00

Session III

CHEMOTHERAPY

Moderators: Giampaolo Tortora (*Rome*), Mario Luppi (*Modena*)

14:00 – 14:40

Can hormone therapy be safely used in kidney transplant recipients with cancer?

Presenter: Giovanni Schinzari (*Rome*)

- 1st discussant: Giuseppe Grandaliano (*Rome*)
- 2nd discussant: Emilio Bria (*Rome*)
- Discussion and voting

14:40 – 15:20

Can anti-angiogenic drugs be safely used in kidney transplant recipients with cancer?

Presenter: Ernesto Rossi (*Rome*)

- 1st discussant: Giuseppe Grandaliano (*Rome*)
- 2nd discussant: Camillo Porta (*Pavia*)
- Discussion and voting

15:20 – 16:00

Can platinum salts be safely used in kidney transplant recipients with cancer?

Presenter: Giovanni Schinzari (*Rome*)

- 1st discussant: Luigi Biancone (*Turin*)
- 2nd discussant: Camillo Porta (*Pavia*)
- Discussion and voting

16:00 – 16:20

Coffee Break

16:20 – 17:00

SUMMARY AND CONCLUSIONS

Jacopo Romagnoli (*Rome*)

INFORMATION

ECM (only for Italian participants)

L'evento è stato accreditato presso la Commissione Nazionale per la Formazione Continua in Medicina (ID evento 282370) e ha ottenuto n. 3 crediti formativi per la figura professionale di

- Medico Chirurgo con la specializzazione nelle seguenti discipline: *Anestesia e Rianimazione; Chirurgia Generale; Dermatologia e Venereologia; Ematologia; Ginecologia E Ostetricia; Nefrologia; Oncologia; Radioterapia; Radiodiagnostica*
- Infermiere
- Infermiere pediatrico

Thanks to the following companies for the unconditional support



Organising Secretariat



Viale Tiziano, 19 – 00196 Rome
Tel. +39 06328121 Fax +39 0239293109
consensus.kidney@ega.it